Genetic Epidemiology of Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum from simple steatosis to steatohepatitis, fibrosis and cirrhosis. Family and twin studies estimate heritability of hepatic fat accumulation at around 25–30%, indicating a substantial genetic component. Early genome-wide association studies (GWAS) identified common variants near PNPLA3, NCAN, GCKR and TM6SF2 that modulate lipid handling, insulin sensitivity and inflammatory response. Subsequent work has revealed both common and rare coding variants that influence disease onset, progression and complications such as hepatocellular carcinoma. Polygenic risk scores integrate numerous loci to stratify individual susceptibility, while trans-ancestral analyses highlight population-specific effects and rare, population-restricted alleles. Multiomics integration—combining genomics, transcriptomics and proteomics with imaging phenotypes—has delineated causal pathways and potential therapeutic targets. Understanding genetic epidemiology is critical for risk prediction, personalised prevention and development of genotype-tailored interventions.

Research from Nature Portfolio

Recent studies have employed large-scale genome and proteome integration to refine the genetic architecture of NAFLD. A multiomics investigation combined magnetic resonance imaging‐derived liver fat measures in over 45,000 participants with genome-wide association, mRNA expression and plasma proteomics. This work uncovered 18 common sequence variants associated with steatosis, four with cirrhosis and identified predicted loss-of-function alleles in MTARC1 and GPAM as protective, suggesting novel drug targets. Protein quantitative trait loci highlighted pathways in lipid synthesis and extracellular matrix remodelling, and proteomic classifiers distinguished early steatosis from cirrhotic stages. In patients with NAFLD‐related hepatocellular carcinoma, deep sequencing of candidate genes demonstrated enrichment of rare pathogenic variants, notably in APOB, and developed a genetic risk score that outperformed traditional clinical predictors for cancer risk stratification.

Genetic Epidemiology of Nonalcoholic Fatty Liver Disease publication trend

The graph below shows the total number of articles in genetic epidemiology of nonalcoholic fatty liver disease across all publications each year (not limited to Nature Index journals).

Technical terms

Genome-wide association study (GWAS): An approach analysing millions of common genetic variants across many individuals to identify loci associated with a trait.

Mendelian randomisation: A method using genetic variants as instrumental variables to infer causal relationships between risk factors and disease.

Polygenic risk score: A weighted sum of risk alleles at multiple loci used to estimate an individual’s genetic predisposition to a disease.

Rare variant: A genetic alteration present at low frequency (<1%) in the population, often with larger effect sizes on disease risk.

Hepatic steatosis: Accumulation of fat droplets within liver cells, the hallmark of early NAFLD.

Cirrhosis: Advanced liver scarring characterised by fibrous tissue deposition and impaired hepatic function.

References

1. Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits. PLOS Genetics (2011).
2. Multiomics study of nonalcoholic fatty liver disease. Nature Genetics (2022).
3. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Reports Medicine (2021).
4. Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports (2019).
5. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. Journal of Hepatology (2020).